Redox signalling and transition metals in the control of the p53 pathway

Biochemical Pharmacology

Volumn 59, Issue 1, 2000, Pages 25-33

  Méplan, Catherine ^a   Richard, Marie Jeanne ^b   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

Apoptosis; Cadmium; Cancer; Cell cycle; Free radicals; p53; Zinc

Indexed keywords

CADMIUM; FREE RADICAL; PROTEIN P53; ZINC;

APOPTOSIS; CANCER INHIBITION; CELL CYCLE; CHEMICAL STRUCTURE; DNA BINDING; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0344210364     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00297-X     Document Type: Conference Paper

References (70)

1. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex Understanding tumorigenic mutations . Science. 265:1994;346-355.
2. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., Stark G.R. The p53 network. J Biol Chem. 273:1998;1-4.
3. Hainaut P., Hollstein M. p53 and human cancer The first ten thousand mutations . Adv Cancer Res. 77:2000;81-137.
4. Graeber T.G., Peterson J.F., Tsai M., Monica K., Fornace A.J. Jr, Giaccia A.J. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 14:1994;6264-6277.
5. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
6. Hainaut P., Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res. 53:1993;1739-1742.
7. Hainaut P., Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:1993;4469-4473.
8. Forrester K., Ambs S., Lupold S.E., Kapust R.B., Spillare E.A., Weinberg W.C., Felley-Bosco E., Wang X.W., Geller D.A., Tzeng E., Billiar T.R., Harris C.C. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA. 93:1996;2442-2447.
9. Tan M., Li S., Swaroop M., Guan K., Oberley L.W., Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem. 274:1999;12061-12066.
10. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 274:1999;10911-10915.
11. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
12. Kaelin W.G. Jr. Another p53 Doppelganger? Science. 281:1998;57-58.
13. Milner J., Cook A., Sheldon M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene. 1:1987;453-455.
14. Hainaut P., Hall A., Milner J. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding. Oncogene. 9:1994;299-303.
15. Hall A.R., Milner J. Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53. Oncogene. 10:1995;561-567.
16. Stephen C.W., Lane D.P. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol. 225:1992;577-583.
17. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
18. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13:1994;3496-3504.
19. Hainaut P., Butcher S., Milner J. Temperature sensitivity for conformation is an intrinsic property of wild-type p53. Br J Cancer. 71:1995;227-231.
20. Milner J. Flexibility The key to p53 function? Trends Biochem Sci. 20:1995;49-51.
21. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr Biol. 4:1994;865-875.
22. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
23. Nelson W.G., Kastan M.B. DNA strand breaks The DNA template alterations that trigger p53-dependent DNA damage response pathways . Mol Cell Biol. 14:1994;1815-1823.
24. Di Leonardo A., Khan S.H., Linke S.P., Greco V., Seidita G., Wahl G.M. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57:1997;1013-1019.
25. Minn A.J., Boise L.H., Thompson C.B. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10:1996;2621-2631.
26. Linke S.P., Clarkin K.C., Di Leonardo A., Tsou A., Wahl G.M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:1996;934-947.
27. WAF1 proteolysis in ME-180 cells. J Biol Chem. 273:1998;5067-5072.
28. Kramer D.L., Vujcic S., Diegelman P., Alderfer J., Miller J.T., Black J.D., Bergeron R.J., Porter C.W. Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 59:1999;1278-1286.
29. Nigro J.M., Aldape K.D., Hess S.M., Tlsty T.D. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res. 57:1997;3635-3639.
30. Ramet M., Castren K., Jarvinen K., Pekkala K., Turpeenniemi-Hujanen T., Soini Y., Paakko P., Vahakangas K. p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis. 16:1995;2117-2124.
31. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
32. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
33. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
34. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
35. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
36. Hall J., Angele S. Radiation, DNA damage and cancer. Mol Med Today. 5:1999;157-164.
37. Smith G.C., Jackson S.P. The DNA-dependent protein kinase. Genes Dev. 13:1999;916-934.
38. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
39. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53 ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways . Cell. 92:1998;725-734.
40. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1997;1175-1184.
41. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
42. Scolnick D.M., Chehab N.H., Stavridi E.S., Lien M.C., Caruso L., Moran E., Berger S.L., Halazonetis T.D. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57:1997;3693-3696.
43. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 19:1999;1202-1209.
44. Waterman M.J., Stavridi E.S., Waterman J.L., Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet. 19:1998;175-178.
45. Jayaraman L., Murthy K.G., Zhu C., Curran T., Xanthoudakis S., Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11:1997;558-570.
46. Xanthoudakis S., Curran T. Redox regulation of AP-1 A link between transcription factor signaling and DNA repair . Adv Exp Med Biol. 387:1996;69-75.
47. Xanthoudakis S., Miao G.G., Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci USA. 91:1994;23-27.
48. Xanthoudakis S., Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 11:1992;653-665.
49. Whitacre C.M., Hashimoto H., Tsai M.L., Chatterjee S., Berger S.J., Berger N.A. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res. 55:1995;3697-3701.
50. Wesierska-Gadek J., Wang Z.Q., Schmid G. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res. 59:1999;28-34.
51. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature. 392:1998;405-408.
52. Blagosklonny M.V., An W.G., Romanova L.Y., Trepel J., Fojo T., Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem. 273:1998;11995-11998.
53. Pavletich N.P., Chambers K.A., Pabo C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:1993;2556-2564.
54. Delphin C., Cahen P., Lawrence J.J., Baudier J. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur J Biochem. 223:1994;683-692.
55. Coffer A.I., Knowles P.P. Divalent metal ions induce conformational change in pure, human wild-type p53 tumor suppressor protein. Biochim Biophys Acta. 1209:1994;279-285.
56. Palecek E., Brazdova M., Cernocka H., Vlk D., Brazda V., Vojtesek B. Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. Oncogene. 18:1999;3617-3625.
57. Hainaut P., Rolley N., Davies M., Milner J. Modulation by copper of p53 conformation and sequence-specific DNA binding Role for Cu(II)/Cu(I) redox mechanism . Oncogene. 10:1995;27-32.
58. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:1993;3167-3174.
59. Rainwater R., Parks D., Anderson M.E., Tegtmeyer P., Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol. 15:1995;3892-3903.
60. Verhaegh G.W., Parat M.O., Richard M.J., Hainaut P. Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. Mol Carcinog. 21:1998;205-214.
61. Wu H.H., Momand J. Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation. J Biol Chem. 273:1998;18898-18905.
62. Verhaegh G.W., Richard M.J., Hainaut P. Regulation of p53 by metal ions and by antioxidants Dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper . Mol Cell Biol. 17:1997;5699-5706.
63. Vallee B.L. Introduction to metallothionein. Methods Enzymol. 205:1991;3-7.
64. Russo T., Zambrano N., Esposito F., Ammendola R., Cimino F., Fiscella M., Jackman J., O'Connor P.M., Anderson C.W., Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem. 270:1995;29386-29391.
65. Parks D., Bolinger R., Mann K. Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA. Nucleic Acids Res. 25:1997;1289-1295.
66. Calmels S., Hainaut P., Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 57:1997;3365-3369.
67. Meplan C, Mann K and Hainaut P, Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in intact cells. J Biol Chem, in press.
68. Zwacka R.M., Zhou W., Zhang Y., Darby C.J., Dudus L., Halldorson J., Oberley L., Engelhardt J.F. Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP1 and NF-kappaB activation. Nat Med. 4:1998;698-704.
69. Clive D.R., Greene J.J. Cooperation of protein disulfide isomerase and redox environment in the regulation of NF-kappaB and AP1 binding to DNA. Cell Biochem Funct. 14:1996;49-55.
70. Nagel W.W., Vallee B.L. Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci USA. 92:1995;579-583.